July 6, 2016

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: 
Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6.

AUTHORS: 
Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group

SUMMARY: 
This substudy showed that NAT significantly altered the genomic signature of the patient’s breast cancer compared with the patient’s pre-treatment genomic profile. These alterations occurred in a subtype-dependent manner, suggesting that NAT may have either eliminated the most susceptible tumor subclone, leaving the treatment resistant clone with a different genetic signature, or altered molecular characteristics of the original cancer.

Read more: Beitsch et al_2016_Annals of Surgical Oncology_Genomic Impact of Neoadjuvant Therapy on Breast Cancer…